NTLA:NSD-Intellia Therapeutics Inc.

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 16.16

Change

0.00 (0.00)%

Market Cap

USD 0.61B

Volume

0.56M

Analyst Target

USD 31.79
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.14 (-0.27%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

+2.75 (+0.29%)

USD 106.98B
MRNA Moderna Inc

+3.18 (+2.96%)

USD 39.68B
ARGX argenx NV ADR

+1.02 (+0.26%)

USD 23.67B
BNTX BioNTech SE

+1.27 (+1.38%)

USD 22.34B
GMAB Genmab AS

-0.20 (-0.65%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

+2.42 (+1.59%)

USD 19.08B
RPRX Royalty Pharma Plc

+0.22 (+0.73%)

USD 18.18B
BGNE BeiGene Ltd

+1.27 (+0.83%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

+0.87 (+0.99%)

USD 16.06B

ETFs Containing NTLA

XDNA 8.89 % 0.00 %

N/A

N/A
MSGR 4.67 % 0.00 %

N/A

N/A
GN0M:XETRA Global X Genomics & Biote.. 3.88 % 0.00 %

+0.10 (+1.30%)

USD 8.88M
CDNA:CA CI Bio-Revolution ETF 3.15 % 0.00 %

N/A

CAD 5.34M
ARKG 0.00 % 0.75 %

N/A

N/A
XSU:CA iShares US Small Cap (CAD.. 0.00 % 0.36 %

+0.89 (+1.30%)

CAD 0.55B
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.39% 49% F 69% C-
Dividend Return N/A N/A N/A N/A F
Total Return 18.39% 49% F 68% D+
Trailing 12 Months  
Capital Gain -31.61% 46% F 21% F
Dividend Return N/A N/A N/A N/A F
Total Return -31.61% 46% F 21% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 16.37% 65% D 73% C
Dividend Return 16.37% 65% D 70% C-
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 45.02% 52% F 23% F
Risk Adjusted Return 36.35% 74% C 51% F
Market Capitalization 0.61B 76% C+ 66% D+

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -8.12 76% 80%
Price/Book Ratio 2.68 53% 38%
Price / Cash Flow Ratio -2.68 73% 85%
Price/Free Cash Flow Ratio -10.36 71% 80%
Management Effectiveness  
Return on Equity -30.59% 72% 26%
Return on Invested Capital -32.57% 73% 26%
Return on Assets -24.96% 76% 23%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector